| Filed | Description | |
|---|---|---|
| 12/18/24 | 1.02 Agreement Terminated | → |
| 2/5/24 | 1.01 Material Agreement | → |
| 12/19/23 | 1.012.03 Material Agreement · New Debt Obligation | → |
| 11/27/23 | 1.01 Material Agreement | → |
| 9/28/23 | 1.01 Material Agreement | → |
| 8/29/23 | 1.01 Material Agreement | → |
| ↓ 9 more | ||
It operates as an privately held independent subsidiary of Novo Holdings A/S. It is a provider of drug delivery technologies, drug development, drug manufacturing, biologics, gene therapy, and consumer health products.